Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Matthew Goetz MD

Matthew P Goetz MD

Professor of Oncology and Pharmacology, Mayo Clinic, Rochester, Minnesota

Matthew P. Goetz, M.D. is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic. He holds the academic rank of Professor of Oncology and Pharmacology. 

Dr. Goetz leads the breast cancer research activities at the Mayo Clinic where he is chair of the Mayo Breast Cancer Research Group, co-leader of the Women’s Cancer Program within the Mayo Clinic Cancer Center, and Co-PI of the Mayo Clinic Breast Cancer Specialized Program of Research Excellence (SPORE) grant. 

Dr. Goetz has been extensively involved in both translational research as well as in the conduct of early and late phase clinical trials. A notable area of Dr. Goetz's focus has been related to the pharmacogenetics of tamoxifen.   Emanating from this work and in collaboration with the Developmental Therapeutics Program of the National Cancer Institute (NCI), Dr. Goetz has led a team of investigators in the development of a novel formulation of endoxifen for the treatment of estrogen receptor positive breast cancer. 


Dr. Goetz reports the following disclosures:

Advisory board:  Myriad, Biotheranostics, Lilly, Biovica, Eisai
Funding:  Lilly, Pfizer